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Background/aim: Familial Mediterranean fever (FMF) is diagnosed by fever episodes with sterile peritonitis, arthritis, pleurisy, and
erysipelas-like erythema. The relationship between phenotype and genotype in FMF has not been adequately explained. The aim of this
study was to characterize the phenotype and genotype correlation in FMF.
Materials and methods: Clinical diagnosis of FMF was conducted according to the Tel Hashomer criteria. Pras scoring was used to
determine clinical severity. FMF strip assay analysis was used, and the hotspot regions were observed with PCR amplification and
automatic DNA sequence analysis method.
Results: We showed commonly seen mutations (most frequently M694V) in a study group of 191 patients. The disease severity score of
patients with M694V mutation was high on the Pras scoring system. Patients with M694V mutation needed high colchicine dosages to
control disease activity. R202Q was the most commonly seen polymorphism in 70 patients. The coexpression of R314R single nucleotide
polymorphism on third exon was shown in our study. Moreover, D102D, G138G, and A165A subhaplotypes and E474E, Q476Q, and
D510D subhaplotypes were also shown.
Conclusion: DNA sequence analysis should be a commonly used method for progress in the field of molecular genetics and for the
better understanding of the FMF phenotype and genotype relationships in all populations.
Key words: Children, familial Mediterranean fever, MEFV, genotype, phenotype

1. Introduction
Familial Mediterranean fever (FMF) is the most common
autoinflammatory hereditary recurrent fever disease. It
affects people from the Mediterranean region, including
Turks, Armenians, non-Ashkenazi Jews, Arabs, and, less
commonly, Greeks and Italians. FMF is an autosomal
recessive hereditary disease linked to a gene named MEFV.
The identification of the MEFV gene on chromosome
16p13.3 initiated the development of genetic diagnostic
tests for FMF (1–3). In more than 80% of typical cases,
MEFV mutations involve nucleotide substitutions at the
last exon (3). The first attack occurs in early childhood
before the age of 10 in 65% of cases (4). The clinical
manifestations are characterized by recurrent, self-limiting
episodes of fever; serositis resulting in pain in the abdomen,
chest, joints, and muscles; abdominal and pleuritic pain;
arthritis; and cutaneous rashes (5). The clinical diagnosis
* Correspondence: kcanturk1@hotmail.com
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is made based on typical clinical manifestations, a positive
response to colchicine therapy, and genetic testing. The
disease is often diagnosed retrospectively on the basis of
unexplained recurrent febrile attacks, positive familial
history, and the exclusion of other illnesses similar to FMF.
Widely used clinical criteria were proposed in Israel in
1997 (5,6). Unfortunately, these criteria were not found to
be very useful in other countries.
FMF is considered as an autosomal recessive disease,
meaning that the presence of two mutations on different
alleles (homozygote or compound heterozygote) makes
it possible to confirm the diagnosis. Some patients
have only one identifiable mutation and others have no
identifiable mutations. When only one mutation exists,
the diagnosis cannot be ascertained or excluded. Families
with members who present typical FMF in the absence
of MEFV mutations have been found in Turkey (7). At
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present, FMF is not entirely understood; however, analysis
of the sequence variants of the MEFV gene in patients with
FMF will lead to a greater comprehension of the disease.
If we prevent delayed diagnosis, urgent early initiation of
colchicine prophylaxis can be started.
The purpose of the present study was to review the
clinical and demographic features of child-onset FMF
patients and to investigate whether there is a phenotype–
genotype correlation.
2. Materials and methods
2.1. Patients
We retrospectively reviewed the medical records of
patients with FMF followed in the Department of Pediatric
Nephrology at the Ege University Faculty of Medicine,
İzmir, Turkey. All patients were of Turkish origin and
living in the Aegean region of Anatolia. Tel Hashomer and
Livneh criteria were used for the clinical diagnosis of FMF,
which is based on major, minor, and supportive criteria.
Diagnosis requires the presence of either 1 major or 2
minor criteria, or 1 minor and 5 supportive criteria (5).
A questionnaire was prepared that requested
information on the demographic status and clinical
manifestations of the patients (fever, abdominal pain,
arthritis, chest pain, and erysipelas-like erythema). We
noted the age at diagnosis, time interval between disease
onset and diagnosis, history of other diseases, and number
of attacks per year before and after treatment. In addition,
we recorded consanguinity, development of amyloidosis,
presence of a family history of FMF and amyloidosis,
and treatment regimen. The presence of chronic renal
disease was discussed and patients were asked for the type
of renal replacement, if present. Response to colchicine
treatment was evaluated as complete (attack-free),
incomplete (decline of >50% in the frequency of attacks),
or unresponsive. The severity score of the disease was
calculated based on the Pras scoring system. This scoring
has 6 conditions including onset age, colchicine dosages,
number of attacks per month, presence of arthritis,
erysipelas-like erythema, and amyloidosis (8). Scores
are as follows: onset age, 0–3 points; attack frequency,
1–3 points; articular findings, 0–3 points; erysipelas-like
erythema, 0–2 points; and occurrence amyloidosis, 0–4
points. Patients were also scored according to the amount
of colchicine required to control disease symptoms: no
response to colchicum (4 points), 2 mg/day (3 points), 1.5
mg/day (2 points), or 1 mg/day (1 point). Scores of 2–5
indicate mild disease, 6–10 show moderate severity, and 10
or more indicate severe disease. Patients presenting with
amyloidosis before the onset of clinical symptoms were
phenotype II. For patients with persistent proteinuria or
nephrotic syndrome, tissue samples were made from the
kidney.

In our study group, none of the patients had
immunological abnormality or other rheumatic disease.
Active clinical presentation types such as fever, abdominal
pain, arthritis, and myalgia were recorded, and laboratory
parameters including high levels of serum amyloid A,
C-reactive protein, fibrinogen, white blood cell counts,
and erythrocyte sedimentation rates were recorded for
each patient.
Mutation analysis was initially done using StripAssay.
Additionally, for patients in whom no mutation was
detected by StripAssay, we carried out bidirectional DNA
sequence analysis in all 10 coding exons and exon–intron
boundaries for the detection of all coding and noncoding
sequence variations along the MEFV gene. Patients in
whom no mutation was detected by both approaches
(StripAssay and sequence analysis) were excluded from
the study.
The study was performed according to the Helsinki
principles. We received informed consent from all patients
or their families. The ethics committee of the Faculty of
Medicine of Ege University reviewed and approved this
study.
The patients were divided into two groups. Group 1
included patients with common mutations present in strip
assay results, and group 2 included patients with coding
and noncoding sequence variations of the MEFV gene in
sequence analysis but no mutation in StripAssay. The two
groups were compared by sex, onset age, age of diagnosis,
time interval between disease onset and diagnosis, clinical
findings of fever, abdominal pain, arthritis, chest pain,
erysipelas-like erythema, amyloidosis, number of attacks
per year before and after colchicine treatment, severity
score, consanguinity, and family history of FMF and
amyloidosis.
2.2. Genetic analysis
DNA was extracted using the QIAamp DNA Blood
Isolation Kit (QIAGEN, Germany) following the
manufacturer’s instructions. The extracted DNA
concentration was measured using a Thermo Scientific
NanoDrop spectrophotometer (Wilmington, DE, USA).
For the quality assessment, 2% agarose gel electrophoresis
was used. For reverse hybridization assay, FMF StripAssay
(ViennaLab, Austria) was used. Multiplex PCR was used
with biotinylated primers for exons at 2×, 3×, 5×, and 10×
amplification. PCR products were hybridized to a test
strip with a parallel array of allele-specific oligonucleotide
probes, including 12 MEFV mutations (E148Q, P369S,
F479L, M680I (G/C), M680I (G/A), I692del, M694V,
M694I, K695R, V726A, A744S, R761H). Sequence analysis
was performed by SeqScape 2.0 (Applied Biosystems,
USA). MEFV hot-spot mutations in exons 10, 2, 3, and 5,
and when needed in exons 1, 4, 6, 7, 8, and 9, were searched
by automated DNA sequence analysis. One microliter of
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genomic DNA was added to polymerase chain reaction
(PCR) amplification buffer. The PCR program included
a hot start denaturation step at 95 °C for 10 min; then
35 amplification cycles of denaturation at 95 °C for 30 s,
annealing at 61 °C for exon 10, 58 °C for exons 2 and 3,
and 57 °C for exon 5 for 40 s, and elongation at 72 °C for
45 s; and a final extension at 72 °C for 7 min. PCR products
were purified using an ExoSAP-IT PCR product clean-up
kit. Cycle sequencing PCR products were purified with
the BigDyeXT kit (Applied Biosystems). Cycle sequencing
reactions were completed with the BigDye Terminator v3.1
cycle sequencing kit (Applied Biosystems). The data were
analyzed using an ABI 3130xl Genetic Analyzer (Applied
Biosystems). The amplicons of exon 5 were digested by the
restriction enzyme Tsp509I. The digestion products were
electrophoresed on a 1% agarose gel. The 4 hot spot regions
(exons 10, 5, 3, and 2) for MEFV mutations were observed
using PCR amplification and automatic DNA sequence
analysis method. One microliter (100 ng) of genomic DNA
was added to amplification buffer, and 10 pmol of each
reverse and forward primer synthesized by Invitrogen and
1.0 U of Platinum Taq PCR DNA polymerase (Invitrogen,
USA) in a total of 25 µL was used. The cycling conditions
comprised a hot start denaturation step at 95 °C for 10
min, then 35 amplification cycles at 95 °C for 30 s and 72
°C for 45 s with a final extension at 72 °C for 7 min. The
primers used are shown below.
Exon 2: sense: 5-ATC TTG GGC CCT AAA CGT
GG-3; antisense: 5-GGG TTC TGT TGC CGA GTC-3.
Exon 3: sense: 5-TAA CTG AGA ACT CGC ACA TCT
C-3; antisense: 5-CTT GTG TTC CAG GGC GAC CTC3. Exon 5: sense: 5-CCA CCT CTT ATC CAC CTC C-3;
antisense: 5-CTT CAC CCA CTT GTT CC-3. Exon
10: sense: 5-GAG GTG GAG GTT GGA GAC AA-3;
antisense: 5-TGA CCA CCC ACT GGA CAG AT-3.
An ABI 3100 Genetic Analyzer was used for cycle
sequencing PCR products after purification with a BigDye
XTerminator kit. DNA was sequenced in both directions.
Seq-Scape 2.0 sequence analysis software was used.
2.3. Statistical analysis
Data were analyzed using SPSS 11.0 (SPSS, Chicago, IL,
USA). Data were categorized as median and range or mean
± standard deviation (SD) according to the normality
of distribution. We compared the categorical data and
proportions by using the chi-square test or Fisher’s exact
test. Means were compared with Student’s t-test, and
medians were compared with the Mann–Whitney U test as
indicated. For all tests, P < 0.05 was considered significant.
3. Results
The study population consisted of 261 children with FMF
(125 boys, 136 girls). The mean age of patients was 104.8
± 49 months. The presence of one or two mutations was
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shown by StripAssay in 191 patients. In the remaining
70 patients, the presence of the coding and noncoding
sequence variations in the MEFV gene was detected by
sequence analysis. Mean follow-up time was 32 ± 26.8
months, and the median was 21 months (minimum 8,
maximum 160 months) (Table 1).
The age of onset was 79.16 ± 43 months for patients
in group 1 and 55.9 ± 31.7 months for patients in group
2. In group 1, the time interval between disease onset and
diagnosis was 31.23 ± 29.1 months. There were statistical
differences between groups with regard to age of onset, age
of diagnosis, and time interval. In group 2, patients had
longer periods of complaint and older age at diagnosis.
The consanguinity rate was 27 (10.3%) in our
population. A positive family history for FMF was noted
in 126 children (48.4%) and for amyloidosis in 8 children
(3%). Two patients had amyloidosis (Table 1).
The most common clinical feature was abdominal
pain (85.4%), followed by fever (58.2%), arthritis (19.1%),
arthralgia (42.5%), chest pain (12.6%), and erysipelas-like
erythema (1.5%). No difference was detected between
groups with regard to fever, abdominal pain, chest pain,
and erysipelas-like erythema, but arthralgia was seen
more in group 1 (Table 1).
The number of attacks per year before and after
treatment was 8 (range: 1–48) and 0.78 ± 2.2 (range: 0–24),
respectively, for 261 patients. Only 2% of the patients had
a severe disease score; 56% of the patients had a moderate
score (Table 2).
Among the 261 patients, 182 (69.7%) had complete
response to colchicine treatment, 67 (25.6%) had
some attacks despite colchicine, and 12 (4.59%) were
unresponsive. Responses to colchicine treatment were
similar in the two groups (Table 2).
None of the patients died or needed renal replacement
therapy. Eleven children underwent surgery, and all had
an appendectomy. Of patients who had appendectomies, 4
were homozygous for R202Q, M680I, and M694V; 5 were
heterozygous for M694V, K695R, M694I, and E148Q; and
2 were compound heterozygous for M694V/V726A and
M694V/E148Q.
There was mild or nephrotic proteinuria in 45 patients
(17.2%). Renal biopsy indicated amyloidosis in 2 of the 12
patients, and amyloidosis was seen in group 1 (Table 1).
Homozygosity for M694V and M680I was found
in 28 (14.6%) and 3 (1.6%) patients, respectively. Four
patients (2%) were homozygous for E148Q. The number
of heterozygotes for the mutations was 50 (26.1%) for
M694V, 6 (3.14%) for M680I, 5 (2.6%) for V726A, and 29
(15.2%) for E148Q. Compound heterozygosity for M694V
mutation was present in 30 patients and most of them were
E148Q/M694V (12 cases, 6.3%) (Table 3).
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Table 1. Summary of phenotypic features.
All population

Group 1

Group 2

P*

n: 261

n: 191

n: 70

Age of onset, (months) mean ± SD

72.9 ± 42.1

79.16 ± 43

55.9 ± 31.7

0.0001

Age of diagnosis, (months) mean ± SD

104.8 ± 49

108 ± 40

95.2 ± 48.6

0.047

Duration of symptoms, (months) mean ± SD

34.8 ± 30.4

31.4 ± 28.09

44.27 ± 34.3

0.005

Time interval between disease onset and diagnosis,
(months) mean ± SD

33.5 ± 31.6

31.23 ± 29.1

39.5 ± 37.2

The duration of follow-up, (months) mean ± SD

32 ± 26.7

Fever, number, %

152 (58.2)

110 (57.5)

42 (58.5)

>0.05

Abdominal pain, number, %

223 (85.4)

162 (84.8)

61 (87)

>0.05

Arthritis, number, %

50 (19.1)

40 (20.9)

10 (14.3)

>0.05

Arthralgia, number, %

111 (42.5)

90 (47.1)

21 (30)

0.013*

Chest pain, number, %

33 (12.6)

27 (14.1)

6 (8.6)

>0.05

Erysipelas-like erythema, number, %

4 (1.5)

4 (2.6)

0

>0.05

Amyloidosis, number, %

2

2 (1.04)

0

Proteinuria, number, %

45 (17.2)

37 (19.3)

8 (11.4)

Consanguinity, number, %

27

20 (10.4)

7 (10)

>0.05

Family history of FMF, number, %

126 (48.4)

90 (47)

36 (51.4)

>0.05

Family history of amyloidosis, number, %

8 (3.06)

6 (3.14)

2 (2.8)

>0.05

Underwent surgery, number, %

11 (4.21)

9 (4.7)

2 (2.8)

>0.05

*Chi-square test.
Table 2. Comparison among disease responses to colchicine therapy, severity score, and colchicine dosage.
Response to colchicine, number, %

P*

Complete

182 (69.7)

129 (67.5)

53 (75.7)

Incomplete

67 (25.6)

51 (26.7)

16 (22.85)

Nonresponsive

12 (4.59)

11 (5.75)

1 (1.42)

Mild

110 (42.1)

87 (45.5)

23 (32.8)

>0.05

Moderate

146 (55.9)

99 (51.8)

47 (67.1)

0.04

Severe

5 (1.91)

5 (2.6)

0

>0.05

0.5 mg/day

45 (17.2)

29 (15.2)

16 (22.8)

>0.05

1 mg/day

187 (71.6)

135 (70.7)

52 (74.3)

>0.05

1.5 mg/day

24 (9.19)

22 (11.5)

2 (2.9)

2 mg/day

5 (1.91)

5 (2.6)

0

Pras disease severity score

Dosage of colchicine

>0.05

*Chi-square test.

1201

YILMAZ et al. / Turk J Med Sci
Table 3. MEFV mutations in StripAssay analysis.
Mutation

Genotype

Number (%)

Homozygous

M694V

28 (14.6)

M680I

3 (1.6)

M694I

1 (0.5)

E148Q

4 (2.0)

P369S

1 (0.5)

F479L

1 (0.5)

M694V

50 (26.1)

M680I

6 (3.14)

M694I

2 (1.0)

E148Q

29 (15.2)

P369S

3 (1.6)

R761H

5 (2.6)

K695R

5 (2.6)

V726A

5 (2.6)

A744S

1 (0.5)

M694V/M680I

9 (4.7)

M694V/M694I

1 (0.5)

M694V/V726A

8 (4.2)

M694V/E148Q

12 (6.3)

E148Q/M680I

1 (0.5)

E148Q/M694I

1 (0.5)

E148Q/P369S

4 (2.09)

E148Q/K695R

1 (0.5)

M680I/R761H

3 (1.6)

M680I/V726A

5 (2.6)

M694I/V726A

1 (0.5)

K695R/A744S

1 (0.5)

Heterozygous

Compound heterozygous

Total

In order to detect the coding and noncoding
sequence variations along the MEFV gene, we performed
bidirectional DNA sequencing analysis in all 10 coding
exons and exon–intron boundaries of the respective gene.
The reported frequencies of common and rare nucleotide
substitutions and synonymous and nonsynonymous single
nucleotide polymorphisms (SNPs) found in group 2 are
seen in Table 4 and the Figure.
Three patients were homozygous for D102D, G138G,
and A165A and heterozygous for R314R, E474E, Q476Q,
and D510D. Six patients were heterozygous for D102D,
G138G, A165A, R314R, E474E, Q476Q, and D510D.
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Recently, the R202Q mutation has been increasingly
included in discussions. Twenty-two patients (31%)
were heterozygous for R202Q and 3 patients (4%) were
homozygous. Six patients were homozygous for the
R314R mutation located on the third exon and 2 were
heterozygous. Heterozygosity for R314R, E474E, Q476Q,
and D510D polymorphism was detected in 21 patients
(Table 4). Haplotype distribution is shown in the Figure.
The most encountered haplotypes in each exon were
E474E, Q476A, and D510D in exon 5; R314R in exon 3;
and D102D, G138G, and A165A in exon 2.
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Table 4. Single nucleotide polymorphisms in group 2.
Single nucleotide polymorphisms

n

D102D, G138G, A165A, R314R, E474E, Q476Q, D510D heterozygote
D102D, G138G, A165A homozygote, R314R, E474E, Q476Q, D510D heterozygote

3
6

R314R, E474E, Q476Q, D510D heterozygote

21

R314R, E474E, Q476Q, D510D homozygote

7

R314R heterozygote

2

R314R homozygote

6

R202Q heterozygote

22

R202Q homozygote

3
28
25

9

E474E, Q476Q,
D510D

5th exon

AGC

8

AGC

GAT

GAT

Figure. SNP haplotype distributions.

4. Discussion
FMF is an inherited autosomal recessive disease, diagnosed
by the recurrent self-limited episodes of fever and serosal
inflammation. FMF is commonly seen in the Middle
East and the Mediterranean region (3,9,10). It is rarely
encountered in other parts of the world. FMF patients
have also been reported from European countries such
as France, Germany, Italy, and Spain. Patients diagnosed
with FMF have also been encountered in the Unites States,
Australia, and Japan (11).
FMF prevalence is 1/500–1/2000 among susceptible
races. FMF carrier rate is 16%–22% (12). FMF prevalence
is 1:400–1.1:1000 in Anatolia, and the carrier frequency
is as high as 1/5 among Turks (11–16). The estimated
prevalence of the disease in Turkey is 0.1% (13). We
reported the frequencies of the MEFV gene mutations,
clinical manifestations, and genotype–phenotype
correlations in 261 children with FMF from the Aegean
region of Turkey.
A male predominance in FMF patients has been
documented in some studies. However, most studies

report that FMF affects both sexes equally. In our study,
the male-to-female ratio showed slight female dominance
(M:F ratio: 1:1.08). In another study from Turkey, M:F
ratio was documented as 1:1.3 (slight female dominance),
although the difference between these figures was not
statistically significant (17).
The onset of clinical manifestations begins before the
age of 5 in 65% of FMF cases and before 20 years of age in
90% of cases. The onset of the disease may occur as early as
6 months of age (18). In our study, the mean age of onset,
mean age at diagnosis, and mean time interval between
disease onset and diagnosis were 79.9 ± 42.1, 104.8 ± 49,
and 33.5 ± 31.6 months, respectively. The mean age at
diagnosis was significantly higher in group 1 than in group
2, and the mean duration of follow-up was similar in both
groups. In our patient cohort, the onset of FMF was at 3–5
years in 144 patients and 6–10 years in 81 patients. The
onset of clinical manifestations in FMF occurred before
the age of 10 in 86% of the cases in our study.
The mean age of onset was 72.9 ± 42.1 months. The
early onset age observed in our study may be explained by
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the early detection of the disease by clinical suspicion and
rapid confirmation by genetic analysis.
Typical clinical findings can vary among different
populations and ethnicities. In Jewish patients, fever and
abdominal pain were more prevalent, while pleurisy and
arthritis were seen more frequently than other findings in
Armenian patients.
The main clinical characteristics of our patients were
as follows: abdominal pain (n: 223, 85.4%), fever (n: 152,
58.2%), myalgia (n: 8, 3.06%), thoracic pain (n: 32, 12.6%),
arthritis (n: 50, 19.1%), arthralgia (n: 111, 42.5%), and
erysipelas-like erythema (n: 4, 1.5%). In our study, the most
common clinical symptom was abdominal pain, similar to
the Turkish FMF study (93.7%). In the Turkish FMF study
(14,15), the arthritis rate was reported as 47.4%. In our
study, percentages were 19.1% for arthritis and 42.5%. for
arthralgia. Two patients developed amyloidosis.
Some patients had typical FMF phenotype, either
with only one MEFV gene mutation or with no mutation
(10,13). Therefore, the disease may be inherited as an
autosomal dominant trait with partial penetration. The
diagnosis is difficult in mild cases and in atypical forms of
the disease.
M694V is encountered in 71% of North African Jews. A
mild mutation, V726A, was found in 38% of East European
Jews (Ashkenazi). A wide range of mutations were seen in
Italians; the most frequently seen mutation is E148Q (18%)
(4,6). M694V and E148Q are the first (32%) and second
(14%) most frequent mutations in Spain, respectively. In
the studies by Touitou et al. (4) and the Turkish FMF study
group (15), the most common MEFV mutations in Turkey
were M694V (57 and 51.4%, respectively), followed by
M680I (16.5 and 14.4%, respectively) and V726A (13.9
and 8.6%, respectively). M694V was the most common
mutation in our study, similarly to many previous studies
(17,19–24). We found that M694V (41.3%) accounted for
the majority of FMF chromosomes, followed by E148Q
(19.9%), M680I (10.3%), V726A (7.2%), P369S (3.06%),
K695R (2.6%), M694I (2.2%), R761H (3.06%), A744S
(0.76%), and F479L (0.38%) (Table 1). The frequencies
of E148Q mutation have been reported to range from
3.5% to 18.3% in Turkey (13,20). We also detected a high
incidence of E148Q mutation (19.9%). At present, E148Q
is considered as a disease-causing mutation, not a benign
polymorphism. The most frequent heterozygous carrier
mutation was E148Q (6.9%). The carrier rate was 16% with
a mutation frequency of 8% in the Turkish population (7).
E148Q is a mild mutation with less penetrance. When
E148Q is part of a complex allele, it has been suggested to
have a cumulative aggravating effect. Patients homozygous
for M694I and M680I, or carrying a combination of both
at codons 694 and 680, have as severe a disease as patients
homozygous for M694V and V726A.
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Amyloidosis is a fatal, devastating complication of FMF
causing renal insufficiency and end-stage renal disease.
Amyloidosis frequency differs between populations (25).
In our study, we found amyloidosis in 2 (0.76%) patients
who were M694V homozygous and M694V/M680I
compound heterozygous. Because all of our patients
were children, they were all informed about the disease
and learned the importance of compliance to colchicum
treatment.
High rates of consanguineous marriages increase the
possibility of transmitting genetic diseases. In our study,
27 patients (10.3%; 15 homozygous, 6 heterozygous,
and 5 compound heterozygous) had a family history
of consanguinity. A history of FMF was seen in 48.4%
of patients. This finding highlights the importance of
molecular diagnosis and sequencing, particularly in the
ancestral populations of FMF.
The clinical spectrum associated with MEFV mutations
ranges from symptom-free to severe complications such
as amyloidosis. Highly penetrant M694V homozygosity
has been demonstrated to correlate with severe disease
in North African Jews, Arabs, and Armenians (99%). In
M694V homozygous patients, frequently seen clinical
features include amyloidosis, early disease onset, and
arthritis. High fever, splenomegaly, and protracted
myalgia are seen more frequently in those patients. In
our study, the percentages of patients with M694V and
with complaints of fever, abdominal pain, and arthritis
were 3, 6, and 3 times higher than those in patients with
other mutations, respectively. Arthritis was seen in 40%
of M694V homozygous and compound heterozygous
patients in our cohort (P = 0.003; P < 0.05). In our study,
the presence of the E148Q mutation was significantly
associated with increased presence of abdominal pain.
In addition, V726A mutation was significantly associated
with increased presence of pleurisy.
Pras score was higher in patients with arthritis,
arthralgia, and myalgia. Most of our patients had moderate
disease (146 cases; 56%). In a study by Pras et al., 80 of
83 patients had M694V mutation in at least one allele.
M694V mutation was homozygous in 70 patients, 12 of
whom developed amyloidosis (25). Five patients with a
severe disease score were M694V homozygous, M694V
homozygous, M694V heterozygous, E148Q heterozygous,
and M694V/M680I heterozygous. The presence of the
M694V mutation increased Pras disease score. Attacks
were controlled by higher doses of colchicum in group
1. M694V homozygosity increases disease severity (P =
0.0001; P < 0.05).
The clinical spectrum changes from the typical
findings of the full-blown disease to asymptomatic
condition. Therefore, the molecular analysis of the MEFV
gene is a useful tool in clinical practice in FMF diagnosis.
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The diagnosis of FMF is made according to the clinical
characteristics and exclusion of other periodic fevers. Thus,
a definite diagnosis is difficult in patients with milder or
atypical manifestations of the disease. For patients whose
MEFV gene does not contain mutations of exons 2, 3, 5,
and 10, we also performed bidirectional DNA sequencing
in exons 1, 4, 6, 7, 8, and 9 (16).
R761H is much more prevalent in Armenians and
Turks. K695R is seen more frequently in Jews (nonAshkenazi and Ashkenazi). A744S is encountered more in
Arabs and F479L in Armenians. R761H mutation was seen
more frequently in our study than in the literature. R761H
mutation was heterozygous in 5 (2.6%) and compound
heterozygous M680I/R761H in 3 (1.6%) patients. In a
previous study from Turkey, it was found that R761H
mutation was heterozygous and compound heterozygous
in 330 of 23 patients (3.48%) (26). It is 4.2% in our study.
In healthy populations, R202Q heterozygosity is
common and is not associated with disease severity (27).
In a study by Giagilis et al., R202Q homozygosity was
present in 12 of 25 FMF patients without any MEFV gene
mutation (27).
We detected additional critical SNPs, of which we have
only limited information for Turkish FMF patients. In the
same study from Greece, DNA sequencing analysis was
made and SNPs were demonstrated. In this study possible
recombination regions were A165A and R202Q, R202Q
and Q476E, and D510D and Q476E. We found R314R,
SNP, D102D, G138G, A165A coexistence and R314R,
E474E, Q476Q, D510D recombination on exon 3. R202Q
heterozygosity was found in 70 patients with sequencing
analysis (Table 4).

We did not observe A165A and R202Q or R202Q
and Q476E coexistence. However, D510D and Q476Q
were found strongly together (38 cases, 54%). R314R was
homozygous in 6 patients. R314R, E474E, Q476Q, and
D510D were heterozygous in 21 patients and homozygous
in 7 patients. There were 4 haplotypes in our study (Figure).
The most commonly seen haplotype was AGCTTAC
(E474E, Q476Q, and D510D-R314R, 28R202Q, R314R).
The presence of a SNP did not carry statistical difference
in terms of clinical findings. The disease severity score was
mild in the SNP group. Incomplete colchicum response
was seen in 23% of patients with SNP. Fortunately, it was
observed that patients in the SNP group needed low doses
of colchicum in order to control disease activity. In R202Q
homozygous patients, frequency in attacks could not
be decreased despite full doses of treatment. In another
study from Spain, a place between R202Q and R314R
was thought of as a hot spot (28). We thought that R314R
may be a hot spot according to our study. Rare mutations
and SNPs have great importance for FMF pathogenesis.
For FMF, heterogeneity exists in phases of alleles,
frequency and critical locations of mutant alleles, and
clinical appearance. With sequencing analysis, we prevent
missing less common variants that might be restricted to
populations by classical methods (16).
Routine screening tests primarily investigate the
most prevalent MEFV mutations. Therefore, we should
primarily research the entire coding sequence of the
MEFV gene before analyzing the other recurrent fever
genes. Eventually, sequence analysis will help prevent rare
population-restricted novel sequence variants from being
overlooked, which is important for the characterization of
typical and atypical FMF (16).

References
1.

Heller H, Sohar E, Pras M. Ethnic distribution and amyloidosis
in familial Mediterranean fever (FMF). Pathol Microbiol 1961;
24: 718–723.

6.

Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean
fever: a survey of 470 cases and review of the literature. Am J
Med 1967; 43: 227–253.

2.

Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B, Le
JM, Barron KS, Holland SM, Kastner DL, Aksentijevich A.
Familial Mediterranean fever with a single MEFV mutation:
where is the second hit? Arthritis Rheum 2009; 60: 1851–1861.

7.

3.

Touitou I. The spectrum of familial Mediterranean fever (FMF)
mutations. Eur J Hum Genet 2001; 9: 473–483.

Berdeli A, Mir S, Nalbantoglu S, Kutukculer N, Sozeri B,
Kabasakal Y, Cam S, Solak M. Comprehensive analysis of a
large-scale screen for MEFV gene mutations: do they truly
provide a “heterozygote advantage” in Turkey? Genet Test Mol
Biomarkers 2011; 15: 475–482.

8.

4.

Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh
A, Cattan D, Yalçinkaya F, Özen S, Majeed H, Ozdogan H et
al. Country as the primary risk factor for renal amyloidosis in
familial Mediterranean fever. Arthritis Rheum 2007; 56: 1706–
1712.

Pras E, Livneh A, Balow JE Jr, Pras E, Kastner DL, Pras M,
Langevitz P. Clinical differences between North African and
Iraqi Jews with familial Mediterranean fever. Am J Med Genet
1998; 75: 216–219.

9.

Shinar Y, Livneh A, Langevitz P, Zaks N, Aksentijevich I,
Koziol DE, Kastner DL, Pras M, Pras E. Genotype-phenotype
assessment of common genotypes among patients with familial
Mediterranean fever. J Rheumatol 2000; 27: 1703–1707.

5.

Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T,
Migdal A, Padeh S, Pras M. Criteria for the diagnosis of familial
Mediterranean fever. Arthritis Rheum 1997; 40: 1879–1885.

1205

YILMAZ et al. / Turk J Med Sci
10.

Dewalle M, Domingo C, Rozenbaum M, Ben-Chétrit E, Cattan
D, Bernot A, Dross C, Dupont M, Notarnicola C, Levy M et
al. Phenotype-genotype correlation in Jewish patients suffering
from familial Mediterranean fever (FMF). Eur J Hum Genet
1998; 6: 95–97.

11.

Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the
world. Arthritis Rheum 2009; 61: 1447–1453.

12.

Ureten K, Gönülalan G, Akbal E, Güneş F, Akyürek O,
Ozbek M, Oztürk MA. Demographic, clinical and mutational
characteristics of Turkish familial Mediterranean fever patients:
results of a single center in Central Anatolia. Rheumatol Int
2010; 30: 911–915.

13.

Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbas
N, Saatci U, Bakkaloglu A, Ozguc M. Mutation frequency of
familial Mediterranean fever and evidence for a high carrier
rate in the Turkish population. Eur J Hum Genet 2001; 9: 553–
555.

14.

Yalçinkaya F, Cakar N, Misirlioğlu M, Tümer N, Akar N, Tekin
M, Taştan H, Koçak H, Ozkaya N, Elhan AH. Genotypephenotype correlation in large group of Turkish patients
with familial Mediterranean fever: evidence for mutationindependent amyloidosis. Rheumatology 2000; 39: 67–72.

20.

Solak M, Yildiz H, Koken R, Erdogan M, Eser B, Sen T, Evirgen
N, Erdem S, Arikan E. Analysis of familial Mediterranean fever
gene mutations in 202 patients with familial Mediterranean
fever. Genet Test 2008; 12: 341–344.

21.

Ben-Chetrit E, Lerer I, Malamud E, Domingo C, Abeliovich D.
The E148Q mutation in the MEFV gene: is it a disease-causing
mutation or a sequence variant? Hum Mutat 2000; 15: 385–
386.

22.

Majeed HA, El-Shanti H, Al-Khateeb MS, Rabaiha ZA.
Genotype/phenotype correlations in Arab patients with
familial Mediterranean fever. Semin Arthritis Rheum 2002; 31:
371–376.

23.

Inal A, Yilmaz M, Kendirli SG, Altintas DU, Karakoc GB. The
clinical and genetical features of 124 children with familial
Mediterranean fever: experience of a single tertiary center.
Rheumatol Int 2009; 29: 1279–1285.

24.

Caglayan AO, Demiryilmaz F, Ozyazgan I, Gumus H.
MEFV gene compound heterozygous mutations in familial
Mediterranean fever phenotype: a retrospective clinical and
molecular study. Nephrol Dial Transplant 2010; 25: 2520–2523.

25.

Pras E, Langevitz P, Livneh A, Zemer D, Migdal A, Padeh
S, Lubetzky A, Aksentijevich I, Centola M, Zaks N et al.
Genotype-phenotype correlation in familial mediterranean
fever (a preliminary report). In: Sohar E, Gafni J, Pras M,
editors. Familial Mediterranean Fever. Tel Aviv, Israel: Freund
Publishing House; 1997. pp. 260–264.

15.

Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O,
Yalcinkaya F, Tutar E, Ozen S, Topaloglu R, Yilmaz E et al.
Familial Mediterranean fever (FMF) in Turkey: results of a
nationwide multicenter study. Medicine 2005; 84: 1–11.

16.

Berdeli A, Nalbantoglu S. The prototype of hereditary periodic
fevers: familial Mediterranean fever. In: Cooper DN, Chen J,
editors. Mutations in Human Genetic Disease. Rijeka, Croatia:
InTech; 2012. pp. 149–166.

26.

Demirkaya E, Tunca Y, Gok F, Ozen S, Gul D. A very frequent
mutation and remarkable association of R761H with M694V
mutations in Turkish familial Mediterranean fever patients.
Clin Rheumatol 2008; 27: 729–732.

17.

Duşunsel R, Dursun I, Gündüz Z, Poyrazoğlu MH, Gürgöze
MK, Dundar M. Genotype-phenotype correlation in children
with familial Mediterranean fever in a Turkish population.
Pediatr Int 2008; 50: 208–212.

27.

18.

Gedalia A. Hereditary periodic fever syndrome. In: Behrman
RE, Kliegman RM, Jenson HB, Stanton BF, editors. Nelson
Textbook of Pediatrics. 18th ed. Philadelphia, PA, USA: WB
Saunders; 2007. pp. 1029–1033.

Giaglis S, Papadopoulos V, Kambas K, Doumas M, Tsironidou
V, Rafail S, Kartalis, G, Speletas M, Ritis K. MEFV alterations
and population genetics analysis in a large cohort of Greek
patients with familial Mediterranean fever. Clin Genet 2007;
71: 458–467.

28.

19.

Topaloglu R, Ozaltin F, Yilmaz E, Ozen S, Balci B, Besbas N,
Bakkaloglu A. E148Q is a disease-causing MEFV mutation: a
phenotypic evaluation in patients with familial Mediterranean
fever. Ann Rheum Dis 2005; 64: 750–752.

Aldea A, Calafell F, Aróstegui JI, Lao O, Rius J, Plaza S, Masó
M, Vives J, Buades J, Yagüe J. The west side story: MEFV
haplotype in Spanish FMF patients and controls, and evidence
of high LD and a recombination “hot spot” at the MEFV locus.
Hum Mutat 2004; 23: 399–406.

1206

